Searchable abstracts of presentations at key conferences in endocrinology

ea0035p1097 | Thyroid Cancer | ECE2014

Do the poorly differentiated and undifferentiated thyroid carcinomas could be the next candidates to somatostatin analoques treatment?

Pisarek Hanna , Pawlikowski Marek , Marchlewska Magdalena , Minias Radoslaw , Winczyk Katarzyna

Introduction: The multimodal management of poorly differentiated thyroid carcinomas (PDTC) and anaplastic carcinomas (ATC) include surgical thyroidectomy, radioiodine treatment, and cytotoxic chemotherapy. Patients with distant metastases which do not respond to radiotherapy could be treated with new therapeutic possibilities like tyrosine kinase inhibitors. PPARĪ³ or mutant P53 are also candidates to PDTC and ATC treatment. Somatostatin and its analogs, demonstrate antipr...